Why does NCCN still not recommend using circulating tumor cells to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?  

While I cannot speak to that panel itself, I can support the very rigorous process that all NCCN guidelines undergo, and I surmise that the reason why ctDNA is not yet recommended is because there is no consensus that: It is better than CEA and good quality cross-sectional imaging (see, for example...